Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study

Department

Internal Medicine

Document Type

Article

Publication Title

Leukemia & Lymphoma

Abstract

Prior studies report a greater incidence of second primary malignancy (SPM) among patients with myeloproliferative neoplasms, although the true risk in primary myelofibrosis (PMF) has not been elucidated. We utilized the Surveillance, Epidemiology, and End Results database to evaluate the risk of SPM in PMF patients and analyzed the effects of sociodemographic factors on the risk of SPM. Out of 5273 patients, 385 patients (7.30%) developed SPM. SPM occurred at SIR of 1.95 (95% CI 1.76–2.15) and AER of 149.01 per 10,000 population. A significantly higher incidence of melanoma (SIR 1.76, 95% CI 1.01–2.86), lymphoma (SIR 3.38, 95% CI 2.28–4.83), and leukemia (SIR 27.19, 95% CI 23.09-31.81) was observed. The risk was significantly higher in patients ≤ 60 years, males, chemotherapy recipients, within 5 years of PMF diagnosis, and for PMF diagnosed after 2009.

First Page

3456

Last Page

3461

DOI

10.1080/10428194.2022.2123227

Volume

63

Issue

14

Publication Date

12-1-2022

Medical Subject Headings

Male; Humans; Neoplasms, Second Primary (etiology); SEER Program; Primary Myelofibrosis (complications); Lymphoma (complications); Incidence; Risk Factors

PubMed ID

36120968

Link to Full Text

Share

COinS